Display options
Cite
Meyer-Sabellek W, Agrawal B. Antihypertensive profile of carvedilol. Clin Investig. 1992;70:S43-52doi: 10.1007/BF00207611.
Meyer-Sabellek, W., & Agrawal, B. (1992). Antihypertensive profile of carvedilol. The Clinical investigator, 70S43-52. https://doi.org/10.1007/BF00207611
Meyer-Sabellek, W, and Agrawal, B. "Antihypertensive profile of carvedilol." The Clinical investigator vol. 70 (1992): S43-52. doi: https://doi.org/10.1007/BF00207611
Meyer-Sabellek W, Agrawal B. Antihypertensive profile of carvedilol. Clin Investig. 1992;70:S43-52. doi: 10.1007/BF00207611. PMID: 1350484.
Copy Download .nbib Format: NLM
Share it on

Clin Investig. 1992;70:S43-52. doi: 10.1007/BF00207611.

Antihypertensive profile of carvedilol.

The Clinical investigator

W Meyer-Sabellek, B Agrawal

Affiliations

  1. Boehringer Mannheim, Cardiovascular Department.

PMID: 1350484 DOI: 10.1007/BF00207611

Abstract

The spectrum of demands on an antihypertensive agent is constantly increasing. It is not only supposed to reduce blood pressure, but also to have a certain profile with regard to pathophysiology, hemodynamics, pharmacokinetics, safety, and clinical applicability. Carvedilol is a new beta-blocking agent without ISA, which causes vasodilation primarily through an alpha 1-blockade. It combines the positive effects of alpha 1- and beta-blockade; the negative properties are offset by each other. It not only provides theoretical advantages, but also shows a favourable hemodynamic profile and is effective and safe. Advantages in both primary and secondary prevention can be expected. It can be administered once daily, is well suited to patient needs, and can be combined with other hypertensive drugs. It also exerts a favorable influence on many secondary diseases. The compelling advantages of the drug make it an important addition to our armamentarium for the treatment of arterial hypertension as a first-line drug.

References

  1. J Intern Med Suppl. 1991;735:113-7 - PubMed
  2. Stroke. 1989 Apr;20(4):473-6 - PubMed
  3. Eur J Clin Pharmacol. 1990;38 Suppl 2:S120-1 - PubMed
  4. Am J Cardiol. 1986 Nov 1;58(10):916-21 - PubMed
  5. J Cardiovasc Pharmacol. 1987;10 Suppl 11:S130-6 - PubMed
  6. Am Heart J. 1991 Mar;121(3 Pt 2):990-4; discussion 994-5 - PubMed
  7. Eur J Clin Pharmacol. 1990;38 Suppl 2:S89-95 - PubMed
  8. J Hypertens Suppl. 1990 Dec;8(6):S33-8 - PubMed
  9. J Cardiovasc Pharmacol. 1991;18 Suppl 4:S12-6 - PubMed
  10. J Hypertens Suppl. 1990 Dec;8(6):S17-20 - PubMed
  11. Eur J Clin Pharmacol. 1984;27(1):19-22 - PubMed
  12. J Cell Physiol. 1983 Aug;116(2):167-72 - PubMed
  13. N Engl J Med. 1990 May 31;322(22):1561-6 - PubMed
  14. Drugs. 1988;36 Suppl 6:129-35 - PubMed
  15. Eur Heart J. 1987 Sep;8(9):928-44 - PubMed
  16. J Hypertens. 1991 Jan;9(1):3-15 - PubMed
  17. Clin Pharmacol Ther. 1986 Jun;39(6):677-82 - PubMed
  18. J Cardiovasc Pharmacol. 1987;10 Suppl 11:S81-4 - PubMed
  19. J Hypertens Suppl. 1990 Dec;8(6):S3-10 - PubMed
  20. Z Kardiol. 1989;78 Suppl 3:21-7 - PubMed
  21. N Engl J Med. 1985 Nov 21;313(21):1315-22 - PubMed
  22. J Cardiovasc Pharmacol. 1987;10 Suppl 11:S141-6 - PubMed
  23. Clin Investig. 1992;70 Suppl 1:S53-7 - PubMed
  24. J Cardiovasc Pharmacol. 1991;18 Suppl 4:S29-34 - PubMed
  25. Eur J Clin Pharmacol. 1990;38 Suppl 2:S104-7 - PubMed
  26. Drugs. 1988;36 Suppl 6:136-40 - PubMed
  27. J Cardiovasc Pharmacol. 1987;10 Suppl 11:S113-8 - PubMed
  28. Eur J Clin Pharmacol. 1990;38 Suppl 2:S139-42 - PubMed
  29. J Cardiovasc Pharmacol. 1987;10 Suppl 11:S85-8 - PubMed
  30. Circulation. 1987 Jan;75(1):131-8 - PubMed
  31. Lancet. 1990 Mar 31;335(8692):765-74 - PubMed
  32. J Cardiovasc Pharmacol. 1987;10 Suppl 11:S119-23 - PubMed
  33. Circulation. 1989 Apr;79(4):733-43 - PubMed
  34. Am J Cardiol. 1985 Jul 1;56(1):35-40 - PubMed
  35. Eur J Clin Pharmacol. 1990;38 Suppl 2:S164-6 - PubMed
  36. Am J Cardiol. 1990 Nov 1;66(15):1118-23 - PubMed
  37. Eur J Clin Pharmacol. 1990;38 Suppl 2:S143-6 - PubMed
  38. Eur J Clin Pharmacol. 1990;38 Suppl 2:S167-70 - PubMed
  39. Clin Investig. 1992;70 Suppl 1:S58-64 - PubMed
  40. Z Kardiol. 1991;80 Suppl 1:21-7 - PubMed
  41. J Cardiovasc Pharmacol. 1991;18 Suppl 4:S62-8 - PubMed
  42. Eur J Clin Pharmacol. 1990;38 Suppl 2:S96-100 - PubMed
  43. Drugs. 1988;36 Suppl 6:31-6 - PubMed
  44. Am Heart J. 1991 Apr;121(4 Pt 2):1274-82 - PubMed
  45. J Hypertens. 1984 Oct;2(5):529-34 - PubMed
  46. Drugs. 1988;36 Suppl 6:92-101 - PubMed
  47. J Cardiovasc Pharmacol. 1987;10 Suppl 11:S124-9 - PubMed
  48. J Hypertens Suppl. 1990 Dec;8(6):S125-34 - PubMed
  49. Eur J Clin Pharmacol. 1990;38 Suppl 2:S125-8 - PubMed
  50. J Cardiovasc Pharmacol. 1987;10 Suppl 11:S42-8 - PubMed
  51. Dtsch Med Wochenschr. 1984 Feb 24;109(8):306-13 - PubMed
  52. Cardiovasc Drugs Ther. 1990 Aug;4(4):1135-43 - PubMed
  53. J Cardiovasc Pharmacol. 1987;10 Suppl 11:S97-100 - PubMed
  54. Am J Cardiol. 1987 Apr 1;59(8):769-74 - PubMed
  55. J Hypertens Suppl. 1990 Dec;8(7):S219-24 - PubMed
  56. J Hypertens Suppl. 1990 Dec;8(6):S43-7 - PubMed
  57. Eur Heart J. 1991 Jan;12(1):60-4 - PubMed
  58. Z Kardiol. 1989;78 Suppl 3:7-15 - PubMed
  59. J Cardiovasc Pharmacol. 1987;10 Suppl 11:S101-7 - PubMed
  60. JAMA. 1982 Feb 19;247(7):992-6 - PubMed
  61. Eur J Clin Pharmacol. 1990;38 Suppl 2:S115-9 - PubMed
  62. J Cardiovasc Pharmacol. 1987;10 Suppl 11:S94-6 - PubMed
  63. Clin Sci Mol Med Suppl. 1978 Dec;4:3s-22s - PubMed

Substances

MeSH terms

Publication Types

LinkOut - more resources